Principal Financial Group Inc. Sells 34,427 Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

Principal Financial Group Inc. reduced its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 4.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 756,707 shares of the company's stock after selling 34,427 shares during the quarter. Principal Financial Group Inc. owned about 1.32% of Structure Therapeutics worth $13,099,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in shares of Structure Therapeutics during the 4th quarter worth about $34,000. Virtus ETF Advisers LLC grew its position in shares of Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares during the period. Assetmark Inc. grew its position in shares of Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after buying an additional 953 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Structure Therapeutics by 673.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock worth $111,000 after buying an additional 3,549 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of Structure Therapeutics during the 4th quarter worth about $113,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GPCR has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. HC Wainwright decreased their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Citigroup initiated coverage on Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective for the company. Finally, JMP Securities reiterated a "market outperform" rating and issued a $89.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $76.17.

Structure Therapeutics Stock Performance

NASDAQ GPCR traded up $0.36 during trading on Wednesday, hitting $19.59. The stock had a trading volume of 544,858 shares, compared to its average volume of 833,498. The company has a market capitalization of $1.12 billion, a PE ratio of -22.52 and a beta of -1.87. The company's 50-day moving average price is $22.14 and its two-hundred day moving average price is $22.95. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $13.22 and a 12 month high of $47.48.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). As a group, equities analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.